Valder R. Arruda
Children's Hospital of Philadelphia · 247 works · 13,780 citations · h-index 51
Top works
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
- Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
- Geographic Distribution of the 20210 G to A Prothrombin Variant
- AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
- The Mutation Ala677→Val in the Methylene Tetrahydrofolate Reductase Gene: A Risk Factor for Arterial Disease and Venous Thrombosis
- Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
- Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
- Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
- Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
- Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer
- X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
- Prevalence of the Prothrombin Gene Variant (nt20210A) in Venous Thrombosis and Arterial Disease
- Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males
- Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism
- Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model
- Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null Mutation
- Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
- Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX